The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Strategies for extended serum half-life of protein therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 478
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Schellenberger, V., Wang, C.-W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1588 · Cited by 462
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368
Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography
Wartiovaara, J., Öfverstedt, L.-G., Khoshnoodi, J., Zhang, J., Mäkelä, E., Sandin, S., Ruotsalainen, V., Cheng, R. H., Jalanko, H., Skoglund, U., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22562 · Cited by 319
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Pharmacokinetic aspects of biotechnology products
Tang, L., Persky, A. M., Hochhaus, G., & Meibohm, B. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20125 · Cited by 303
Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin
Tuan Giam Chuang, V., Kragh-Hansen, U., & Otagiri, M. (2002) · Pharmaceutical Research · doi:10.1023/a:1015396825274 · Cited by 295
Albumin Binding to FcRn: Distinct from the FcRn−IgG Interaction
Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Kontermann, R. E. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00003 · Cited by 243
Self-citationA Portable Albumin Binder from a DNA‐Encoded Chemical Library
Dumelin, C. E., Trüssel, S., Buller, F., Trachsel, E., Bootz, F., Zhang, Y., Mannocci, L., Beck, S. C., Drumea‐Mirancea, M., Seeliger, M. W., et al. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200704936 · Cited by 233
Müller, D., Karle, A., Meißburger, B., Höfig, I., Stork, R., & Kontermann, R. E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700820200 · Cited by 222
Self-citationImproving the therapeutic efficacy of peptides and proteins: A role for polysialic acids
Gregoriadis, G., Jain, S., Papaioannou, I., & Laing, P. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.06.007 · Cited by 202
Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc‐Porekar, V., Zore, I., Podobnik, B., & Menart, V. (2008) · PubMed · Cited by 197
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
Disulfide bridge based PEGylation of proteins
Brocchini, S., Godwin, A., Balan, S., Choi, J.-W., Zloh, M., & Shaunak, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.014 · Cited by 186
Andersen, J. T., Pehrson, R., Tolmachev, V., Daba, M. B., Abrahmsén, L., & Ekblad, C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164848 · Cited by 177
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Huang, C. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.010 · Cited by 166
Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
Weimer, T., Kronthaler, U., Lang, W., Schulte, S., & Metzner, H. J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-04-0255 · Cited by 159
Sarkar, C. A., Lowenhaupt, K., Horan, T. P., Boone, T. C., Tidor, B., & Lauffenburger, D. A. (2002) · Nature Biotechnology · doi:10.1038/nbt725 · Cited by 152
Why Do We Not All Have Proteinuria? An Update of Our Current Understanding of the Glomerular Barrier
Haraldsson, B. S., & Sörensson, J. (2004) · Physiology · doi:10.1152/nips.01461.2003 · Cited by 142
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Self-citationHow Does the Kidney Filter Plasma?
Tryggvason, K., & Wartiovaara, J. (2005) · Physiology · doi:10.1152/physiol.00045.2004 · Cited by 126
Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives
Stork, R., Campigna, E., Robert, B., Müller, D., & Kontermann, R. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.027078 · Cited by 114
Self-citationStork, R., Müller, D., & Kontermann, R. E. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm061 · Cited by 111
Self-citationStork, R., Zettlitz, K. A., Müller, D., Rether, M., Hanisch, F., & Kontermann, R. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709179200 · Cited by 99
Self-citationNelson, D. R., Benhamou, Y., Chuang, W., Lawitz, E., Rodriguez‐Torres, M., Flisiak, R., Rasenack, J. W. F., Kryczka, W., Lee, C., Bain, V. G., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.062 · Cited by 98
Hopp, J., Hornig, N., Zettlitz, K. A., Schwarz, A. E., Fuss, N., Müller, D., & Kontermann, R. E. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq058 · Cited by 90
Self-citationNew Strategy for the Extension of the Serum Half-Life of Antibody Fragments
Trüssel, S., Dumelin, C. E., Frey, K., Villa, A., Buller, F., & Neri, D. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9002772 · Cited by 89
An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and LongIn VivoHalf-Life
Xie, D., Cheng, Y., Wang, L., Min, W., Xu, J., Xiao, J., Huang, M., Chen, B., Liu, B., Li, X., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00976-09 · Cited by 85
A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
Yeung, Y. A., Wu, X., Reyes, A. E., Vernes, J.-M., Lien, S., Lowe, J. A., III, Maia, M., Forrest, W. F., Meng, Y. G., Damico, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4580 · Cited by 80
Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin fusion protein
Yazaki, P. J., Kassa, T., Cheung, C. W., Crow, D. M., Sherman, M. A., Bading, J. R., Anderson, A.-L. J., Colcher, D. M., & Raubitschek, A. A. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.10.010 · Cited by 69
Half-life extension through albumin fusion technologies
Schulte, S. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70157-4 · Cited by 68
Walker, A. R., Dunlevy, G., Rycroft, D., Topley, P., Holt, L. J., Herbert, T., Davies, M. L., Cook, F., Holmes, S., Jespers, L. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp091 · Cited by 67
Melmed, G., Targan, S., Yasothan, U., Hanicq, D., & Kirkpatrick, P. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2654 · Cited by 63
Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment
Constantinou, A., Epenetos, A. A., Hreczuk-Hirst, D., Jain, S., Wright, M., Chester, K. A., & Deonarain, M. P. (2009) · Bioconjugate Chemistry · doi:10.1021/bc8005122 · Cited by 62
Geething, N. C., To, W., Spink, B. J., Scholle, M. D., Wang, C., Yin, Y., Yao, Y., Schellenberger, V., Cleland, J. L., Stemmer, W. P. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010175 · Cited by 61
Kiss, Z., Elliott, S. G., Jedynasty, K., Tesař, V., & Szegedi, J. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0780-y · Cited by 61
Fares, F., Guy, R., Bar-Ilan, A., Felikman, Y., & Fima, E. (2010) · Endocrinology · doi:10.1210/en.2009-1431 · Cited by 57
Fares, F., Ganem, S., Hajouj, T., & Agai, E. (2007) · Endocrinology · doi:10.1210/en.2007-0026 · Cited by 53
Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate
Ceaglio, N., Etcheverrigaray, M., Conradt, H. S., Grammel, N., Kratje, R. B., & Oggero, M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.12.020 · Cited by 44
Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins
Kenanova, V. E., Olafsen, T., Salazar, F. B., Williams, L. E., Knowles, S. M., & Wu, A. M. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq054 · Cited by 42
Evans, L. R., Hughes, M., Waters, J., Cameron, J., Dodsworth, N., Tooth, D., Greenfield, A., & Sleep, D. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.05.009 · Cited by 40
Lao, B. J., & Kamei, D. T. (2007) · Biotechnology Progress · doi:10.1021/bp070080b · Cited by 15
Cited by
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Self-citationPharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 682
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Metadata
- Authors
- Kontermann, R. E.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 22
- Issue
- 6
- Pages
- 868-876
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2027268124
- Cited by
- 573
- References
- 54
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.